Starbucks wins dismissal of Missouri lawsuit over DEI policies

Companies Reviewing GLP-1 Coverage Should Also Review Transgender Healthcare Coverage 

According to reports earlier this month, Starbucks is ending GLP-1 coverage for its employees. Under its new healthcare plan, Starbucks will no longer cover prescription drugs used for weight loss, but it will continue to cover comprehensive transgender healthcare interventions, including reconstructive surgical procedures and puberty blockers, for covered dependents. Employers are pulling back on GLP-1 coverage largely for the same reason they are reconsidering other benefits: to adjust to rising healthcare costs. RxBenefits reports that GLP-1 drugs cost roughly $1,000–$1,500 per month, while SHRM estimates employers often shoulder 70–100% of prescription drug costs.  With GLP-1s now accounting for around 20% of prescription drug spending and the number of users accelerating, employers face a limited set of choices: tighten eligibility requirements, shift more of the cost to employees or customers, or eliminate coverage altogether.  If companies can reasonably reconsider GLP-1 coverage because of cost, uncertain return on investment, and broader questions over what an employer-sponsored health plan should cover, why should other expensive medical benefits, such as transgender medical interventions, be exempt from similar scrutiny?  According to February 2026 data from the Human Rights Campaign, more than 550 major companies, including Starbucks, offer comprehensive transgender healthcare benefits to employees and covered dependents. While …

250 Major Companies Still Use SPLC to Screen Donations, Despite KKK Funding Scandal

Shareholders to Confront Starbucks on Covering Transition—but Not Detransition

Opinion: Corporate leaders flee the result of left-wing agendas they supported

Florida Attorney General Sues Starbucks Over DEI Policies

Bennett Nuss: Missouri v. Starbucks May Be the Blueprint for a Federal Anti-DEI Campaign